Daratumumab in rituximab-refractory autoimmune haemolytic anaemia.

Autor: Rieger MJ; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Stolz SM; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Ludwig S; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Benoit TM; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Bissig M; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Widmer CC; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Schwotzer R; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Müller AM; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Nair G; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Hegemann I; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland., Schanz U; Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2021 Sep; Vol. 194 (5), pp. 931-934. Date of Electronic Publication: 2021 Jun 28.
DOI: 10.1111/bjh.17655
Databáze: MEDLINE